sox3 Antibody

What is SOX3 and why is it an important research target?

SOX3 is a transcription factor required during the formation of the hypothalamo-pituitary axis. In humans, the canonical protein has a reported length of 446 amino acid residues and a mass of 45.2 kDa, with subcellular localization in the nucleus . It functions as a developmental regulator that keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppressing neuronal differentiation . Recent research also suggests SOX3 may serve as a prognostic marker in certain cancers, including gastric carcinoma .

What types of SOX3 antibodies are available for research applications?

SOX3 antibodies are available in several formats:

• Host species: Rabbit, goat, and mouse antibodies are common

• Clonality: Both monoclonal (e.g., clone 287403) and polyclonal antibodies are available

• Target regions: Antibodies targeting different epitopes, including:

  • N-terminal region antibodies

  • C-terminal region antibodies (e.g., against C-DAASPLPGGRLHGVH sequence)

  • Specific amino acid regions (e.g., AA 4-118, AA 84-206, AA 375-446)

What species reactivity is available in commercial SOX3 antibodies?

The available SOX3 antibodies demonstrate reactivity against various species:

When selecting an antibody, researchers should verify species cross-reactivity based on their experimental model .

What applications are SOX3 antibodies validated for?

SOX3 antibodies have been validated for multiple applications, with varying performance across different antibody clones:

For each application, it is advisable to use antibodies specifically validated for that technique rather than assuming cross-application performance .

What are the recommended dilutions for SOX3 antibodies in different applications?

Based on the search results, recommended dilutions vary by application and specific antibody:

• Western Blot: 1:500-1:2000 (PACO20396) , 0.5-1.5μg/ml (A84821)

• Immunohistochemistry: 3-5μg/ml (A84821) , 1:500 (ab183606)

• Immunocytochemistry: 10μg/ml (MAB2569, R&D Systems)

• ELISA: 1:2000-1:5000 (PACO20396) , 1:8,000 (A84821)

These dilutions serve as starting points; optimal conditions should be determined experimentally for each laboratory's specific conditions and sample types .

How should samples be prepared for SOX3 detection in different cell types?

Sample preparation varies depending on the cell type and detection method:

For immunofluorescence in NTera-2 cells (human testicular embryonic carcinoma):

• Fix cells by immersion fixation

• For differentiation studies, treatment with retinoic acid may be used

• Use appropriate secondary antibodies (e.g., NorthernLights™ 493-conjugated Anti-Mouse IgG for MAB2569)

For Western blotting of neural progenitors:

• Differentiate ES cells in N2B27 for 4 days

• Prepare nuclear protein lysates (for nuclear proteins like SOX3)

• Include controls like histone H3 (loading control) and alpha-tubulin (to verify absence of cytoplasmic contamination)

For cancer tissue analysis:

• Use paraffin-embedded formalin-fixed tissues according to standard protocols

• For gastric cancer tissues, correlate SOX3 expression with clinicopathological features

How can SOX3 antibodies be used to distinguish between normal and pathological tissue samples?

SOX3 immunostaining can help differentiate between normal and pathological samples:

• In cancer research: SOX3 has been identified as a prognostic marker in gastric cancer, with higher expression levels correlating with poorer outcomes. Immunohistochemistry with SOX3 antibodies can reveal overexpression in cancer tissues compared to normal counterparts .

• In neural development studies: SOX3 antibodies can identify undifferentiated neural progenitor cells versus differentiated neurons. In the 13.5 dpc telencephalic ventricular zone, SOX3 protein is present in every wild-type cell but absent from mutant tissue .

• In cell line characterization: SOX3 is differentially expressed in various cell lines. For example, it is detected in U-251 MG human glioblastoma cells but absent in HDLM-2 human Hodgkin's lymphoma cells, making it useful for cell type identification .

Research has shown that SOX3 levels in cancer tissues significantly correlate with tumor differentiation, lymph node metastasis, primary tumor invasion, and pTNM stage, suggesting its potential as a biomarker .

What experimental controls should be included when working with SOX3 antibodies?

Proper controls are essential for reliable SOX3 antibody-based experiments:

Positive controls:

• NTera-2 human testicular embryonic carcinoma cells (known to express SOX3)

• U-251 MG human glioblastoma cells

• Wild-type embryonic stem cells differentiated toward neural lineage

Negative controls:

• HDLM-2 human Hodgkin's lymphoma cells (SOX3 negative)

• SOX3-null embryonic stem cells or tissues

• Primary antibody omission control

• Isotype control: Goat IgG or Rabbit IgG depending on the host species of the primary antibody

Additional validation controls:

• Comparison of protein expression with mRNA levels (qPCR)

• Use of SOX3 mutant cells (e.g., Sox3-26ala) to confirm antibody specificity

• Use of multiple antibodies targeting different epitopes of SOX3

How can SOX3 expression patterns be correlated with developmental or pathological processes?

SOX3 expression patterns can provide valuable insights into developmental and pathological processes:

In development:

• SOX3 is one of the earliest neural markers in vertebrates and plays a role in specifying neuronal fate

• Immunohistochemistry can track SOX3 expression during the formation of the hypothalamo-pituitary axis

• Studies in chimeric embryos have revealed that SOX3 is required for craniofacial morphogenesis within pharyngeal epithelia

In cancer progression:

For correlative studies, researchers can combine SOX3 immunostaining with markers of cell proliferation, differentiation, or other cancer-associated proteins like MMPs (matrix metalloproteinases) that have been studied alongside SOX3 .

What are common issues in SOX3 immunodetection and how can they be resolved?

Several challenges may arise when using SOX3 antibodies:

Problem: Weak or no signal

• Solution: Optimize antibody concentration. Try different dilutions ranging from 1:500 to 1:2000 for Western blot

• Solution: Ensure proper sample preparation. SOX3 is a nuclear protein, so nuclear extraction protocols should be used for Western blotting

• Solution: Verify that the antibody recognizes the species being tested using validated positive controls

Problem: High background or non-specific binding

• Solution: Increase blocking time or concentration of blocking agent

• Solution: Use more stringent washing conditions

• Solution: Verify antibody specificity using SOX3-null cells as a negative control

Problem: Inconsistent results between techniques

• Solution: Different antibodies may perform better in specific applications. Select antibodies validated for your application

• Solution: Confirm findings using alternative detection methods (e.g., qPCR for transcript levels)

How can SOX3 antibody performance be optimized for specific tissue types?

Optimization strategies for different tissue types:

For brain tissue:

• Use 1:500 dilution for ab183606 on mouse brain tissue sections

• Include antigen retrieval steps for formalin-fixed paraffin-embedded samples

• Consider longer primary antibody incubation times (overnight at 4°C)

For embryonic tissues:

• When examining developmental tissues, use antibodies that have been validated in embryonic samples

• Compare immunostaining patterns with published in situ hybridization data for SOX3 to verify specificity

For cancer tissues:

• For gastric cancer specimens, follow standard IHC protocols with rabbit monoclonal anti-SOX3 antibody

• Correlation with clinicopathological features can help validate staining patterns

What are the key considerations when comparing results from different SOX3 antibodies?

When comparing results from different SOX3 antibodies, researchers should consider:

Epitope recognition differences:

• Antibodies targeting different regions of SOX3 (N-terminal vs. C-terminal) may yield different results

• Some epitopes may be masked in certain protein conformations or interactions

Validation parameters:

• Verify that each antibody has been validated for the specific application and species

• Check literature for previous use of the antibodies in similar experimental contexts

Technical considerations:

• Standardize experimental conditions when comparing antibodies (same sample preparation, blocking conditions, detection method)

• Include positive and negative controls specific to each antibody

• Consider using secondary detection systems matching the host species of each primary antibody

How is SOX3 expression being investigated as a prognostic marker in cancer research?

Recent research has identified SOX3 as a potential prognostic marker in cancer:

A study on gastric cancer patients revealed that:

• SOX3 is overexpressed in cancer tissues compared to normal tissues

• Serum SOX3 levels in stomach cancer patients were significantly higher than in healthy controls

• SOX3 expression levels in cancer tissues significantly correlated with:

  • Tumor differentiation

  • Lymph node metastasis

  • Primary tumor invasion

  • pTNM stage

Analysis of The Cancer Genome Atlas database demonstrated that:

These findings suggest SOX3 antibodies could be valuable tools for cancer prognosis assessment in clinical research settings.

What novel methodologies are being developed for SOX3 detection in research?

While the search results don't specifically mention novel methodologies for SOX3 detection, researchers could consider:

• Multiplex immunofluorescence: Combining SOX3 antibodies with other markers to simultaneously assess multiple proteins in the same sample

• Proximity ligation assays: For detecting SOX3 protein-protein interactions in situ

• Single-cell analysis: Using SOX3 antibodies in single-cell Western blot or mass cytometry approaches

Further research into SOX3 detection methodologies would benefit from combining antibody-based approaches with transcript analysis, particularly in developmental studies where temporal expression patterns are critical.

How are SOX3 antibodies contributing to our understanding of neural development disorders?

SOX3 antibodies have provided valuable insights into neural development:

• SOX3 functions as a switch in neuronal development, keeping neural cells undifferentiated by counteracting proneural proteins

• It is expressed in the central nervous system from the earliest stages of development and is one of the earliest neural markers in vertebrates

• Studies using SOX3 antibodies have revealed its role in specifying neuronal fate

Mutations in SOX3 have been implicated in developmental disorders affecting the hypothalamo-pituitary axis. Immunodetection studies using SOX3 antibodies can help researchers understand how these mutations affect protein expression, localization, and function, potentially leading to new therapeutic approaches for neurodevelopmental disorders.